Cell‐selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting
- 1 February 2001
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 15 (2) , 416-426
- https://doi.org/10.1096/fj.00-0022com
Abstract
Vascular immunotargeting, the administration of drugs conjugated with antibodies to endothelial surface antigens, has the potential for drug delivery to the endothelium. Our previous cell culture studies showed that biotinylated antibodies to PECAM-1 (a highly expressed endothelial surface antigen) coupled with streptavidin (SA, a cross-linking protein that facilitates anti-PECAM internalization and targeting) may provide a carrier for the intracellular delivery of therapeutic enzymes. This paper describes the PECAM-directed vascular immunotargeting of a reporter enzyme (β-galactosidase, β-Gal) in intact animals. Intravenous injection of [125I]SA-β-Gal conjugated with either anti-PECAM or IgG led to a high 125I uptake in liver and spleen, yet β-Gal activity in these organs rapidly declined to the background levels, suggesting rapid degradation of the conjugates. In contrast, anti-PECAM/[125I]SA-β-Gal, but not IgG/[125I]SA-β-Gal, accumulated in the lungs (36.0±1.3 vs. 3.9±0.6% injected dose/g) and induced a marked elevation of β-Gal activity in the lung tissue persisting for up to 8 h after injection (10-fold elevation 4 h postinjection). Using histochemical detection, the β-Gal activity in the lungs was detected in the endothelial cells of capillaries and large vessels. The anti-PECAM carrier also provided 125I uptake and β-Gal activity in the renal glomeruli. Predominant intracellular localization of anti-PECAM/SA-β-Gal was documented in the PECAM-expressing cells in culture by confocal microscopy and in the pulmonary endothelium by electron microscopy. Therefore, vascular immunotargeting is a feasible strategy for cell-selective, intracellular delivery of an active foreign enzyme to endothelial cells in vivo, and thus may be potentially useful for the treatment of acute pulmonary or vascular diseases.—Scherpereel, A., Wiewrodt, R., Christofidou-Solomidou, M., Gervais, R., Murciano, J.-C., Albelda, S. M., Muzykantov, V. R. Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting.Keywords
This publication has 15 references indexed in Scilit:
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999
- Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migrationNature Medicine, 1998
- Immunotargeting of drugs to the pulmonary vascular endothelium as a therapeutic strategyPathophysiology, 1998
- Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release.Journal of Clinical Investigation, 1998
- The biology of PECAM-1.Journal of Clinical Investigation, 1997
- Immunotargeting of antioxidant enzyme to the pulmonary endothelium.Proceedings of the National Academy of Sciences, 1996
- Pleural-based mesothelioma in immune competent rats: A model to study adenoviral gene transferThe Annals of Thoracic Surgery, 1995
- Localization of Multiple Functional Domains on Human PECAM-1 (CD31) by Monoclonal Antibody Epitope MappingCell Adhesion and Communication, 1995
- Tat-mediated delivery of heterologous proteins into cells.Proceedings of the National Academy of Sciences, 1994
- Involvement of Platelet-Endothelial Cell Adhesion Molecule-1 in Neutrophil Recruitment in VivoScience, 1993